KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Other (2016 - 2020)

Regeneron Pharmaceuticals (REGN) has 12 years of Receivables - Other data on record, last reported at $460.8 million in Q3 2020.

  • For Q3 2020, Receivables - Other rose 33.41% year-over-year to $460.8 million; the TTM value through Sep 2020 reached $460.8 million, up 33.41%, while the annual FY2019 figure was $260.6 million, N/A changed from the prior year.
  • Receivables - Other reached $460.8 million in Q3 2020 per REGN's latest filing, up from $389.2 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $468.3 million in Q1 2020 and bottomed at $93.0 million in Q4 2016.
  • Average Receivables - Other over 5 years is $251.2 million, with a median of $232.2 million recorded in 2017.
  • Peak YoY movement for Receivables - Other: plummeted 39.28% in 2016, then surged 108.3% in 2017.
  • A 5-year view of Receivables - Other shows it stood at $93.0 million in 2016, then soared by 108.3% to $193.7 million in 2017, then skyrocketed by 39.01% to $269.3 million in 2018, then fell by 3.22% to $260.6 million in 2019, then soared by 76.82% to $460.8 million in 2020.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $460.8 million in Q3 2020, $389.2 million in Q2 2020, and $468.3 million in Q1 2020.